$SANA

Sana Biotechnology, Inc.

Sana Biotechnology develops ex vivo and in vivo cell engineering therapies for diseases including type 1 diabetes, B cell cancers and B cell mediated autoimmune diseases. Its ex vivo platform uses hypoimmune, or HIP, technology to engineer transplanted cells to evade immune rejection. Its lead ex vivo candidate, SC451, is a stem cell-derived pancreatic islet cell therapy for type 1 diabetes. The company’s in vivo platform uses fusogen-based delivery to modify cells inside the body. Its candidate SG293 delivers genetic material to CD8+ T cells to generate CD19-targeting CAR T cells. Sana’s pipeline also includes UP421, a HIP-modified primary islet cell therapy studied in a patient with type 1 diabetes. The company’s programs are focused on developing cell therapies, with the aim of replacing or adding cells through ex vivo treatment and modifying cells in the body through in vivo delivery. Sana is headquartered in Seattle, Washington.

1
0
1

No SEC Form 4 filings for $SANA in the last 30 days.

See all $SANA insider activity →

Wedbush cuts Sana Biotechnology stock price target on model changes

Wedbush reduced its price target for Sana Biotechnology (NASDAQ:SANA) to $10 from $22, maintaining an Outperform rating. The change reflects model adjustments, excluding hidradenitis suppurativa and updating financing assumptions. Sana's shares have fallen 42% over the past year, trading at $2.40. The company reported a narrower-than-expected Q2 loss of $0.13 per share and holds $160.5 million in cash.

SANA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SANA (Sana Biotechnology, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.

Recent SANA coverage spans earnings, financial news and technology.

What's driving SANA

AlphAI scores every news story that mentions SANA with an AI model for sentiment and relevance, and aggregates insider trades from Sana Biotechnology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SANA

Score

Wedbush cuts Sana Biotechnology stock price target on model changes

Wedbush reduced its price target for Sana Biotechnology (NASDAQ:SANA) to $10 from $22, maintaining an Outperform rating. The change reflects model adjustments, excluding hidradenitis suppurativa and updating financing assumptions. Sana's shares have fallen 42% over the past year, trading at $2.40. The company reported a narrower-than-expected Q2 loss of $0.13 per share and holds $160.5 million in cash.

$SANAHighAI 8/10

Sana Biotechnology Reports Q3 Profit; Advances Cell Therapy Programs Toward Clinical Trials

Sana Biotechnology (SANA) reported Q3 2026 net income of $20.4M, with R&D expenses rising to $33.9M. The company has $121.7M in cash, expecting a runway into mid-2027. SANA advanced cell therapy programs for type 1 diabetes and non-Hodgkin lymphoma, targeting clinical trials in 2026-2027. UP421 showed long-term survival in type 1 diabetes study. SANA stock is up 1.75% to $2.38.

$SANAHighEarnings

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

Sana Biotechnology, Inc. (SANA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on pu

$AVAIMedAI 8/10

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

AVAI Bio, Vertex, and Sana are developing treatments for Type 1 diabetes by replacing insulin-producing beta cells. Vertex's trial showed 10/12 patients stopped using insulin, but all require immunosuppression. Sana's gene-edited cells evaded immune detection. AVAI Bio's joint venture, Insulinova, is testing encapsulated beta cells with Ospedale San Raffaele. No trials or timelines have been announced.

Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?

Sana Biotechnology (SANA) reported a narrower net loss of US$63.64 million and loss per share of US$0.22 in Q2 2026, compared to the previous year, indicating improved cost management. The company's investment narrative hinges on its cell and gene engineering platforms, with key catalysts tied to clinical progress in SC451 for type 1 diabetes and in vivo CAR T programs. Investors weigh these developments against concerns over the company's cash runway and ongoing losses.

$SANAMedEarnings

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Sana Biotechnology, Inc. (SANA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continu

Mayo Clinic tie-up aims to speed a one-time type 1 diabetes therapy

Sana Biotechnology and Mayo Clinic have announced a strategic collaboration to accelerate the development and delivery of SC451, Sana's investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. Mayo Clinic will also make an equity investment in Sana, with an option for an additional investment, supporting a planned clinical trial start targeted for 2026. The partnership aims to standardize protocols, surgical techniques, trial design, and post-treatment care to enable broader and more consistent delivery of the therapy.

Related tickers